Literature DB >> 9353252

Cooperative effects of INK4a and ras in melanoma susceptibility in vivo.

L Chin1, J Pomerantz, D Polsky, M Jacobson, C Cohen, C Cordon-Cardo, J W Horner, R A DePinho.   

Abstract

The familial melanoma gene (INK4a/MTS1/CDKN2) encodes potent tumor suppressor activity. Although mice null for the ink4a homolog develop a cancer-prone condition, a pathogenetic link to melanoma susceptibility has yet to be established. Here we report that mice with melanocyte-specific expression of activated H-rasG12V on an ink4a-deficient background develop spontaneous cutaneous melanomas after a short latency and with high penetrance. Consistent loss of the wild-type ink4a allele was observed in tumors arising in ink4a heterozygous transgenic mice. No homozygous deletion of the neighboring ink4b gene was detected. Moreover, as in human melanomas, the p53 gene remained in a wild-type configuration with no observed mutation or allelic loss. These results show that loss of ink4a and activation of Ras can cooperate to accelerate the development of melanoma and provide the first in vivo experimental evidence for a causal relationship between ink4a deficiency and the pathogenesis of melanoma. In addition, this mouse model affords a system in which to identify and analyze pathways involved in tumor progression against the backdrop of genetic alterations encountered in human melanomas.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9353252      PMCID: PMC316663          DOI: 10.1101/gad.11.21.2822

Source DB:  PubMed          Journal:  Genes Dev        ISSN: 0890-9369            Impact factor:   11.361


  76 in total

Review 1.  The current situation with regard to human melanoma and genetic inferences.

Authors:  N K Hayward
Journal:  Curr Opin Oncol       Date:  1996-03       Impact factor: 3.645

2.  Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a.

Authors:  M Serrano; A W Lin; M E McCurrach; D Beach; S W Lowe
Journal:  Cell       Date:  1997-03-07       Impact factor: 41.582

3.  Tumorigenesis and male sterility in transgenic mice expressing a MMTV/N-ras oncogene.

Authors:  R Mangues; I Seidman; A Pellicer; J W Gordon
Journal:  Oncogene       Date:  1990-10       Impact factor: 9.867

4.  Malignant melanoma in transgenic mice.

Authors:  M Bradl; A Klein-Szanto; S Porter; B Mintz
Journal:  Proc Natl Acad Sci U S A       Date:  1991-01-01       Impact factor: 11.205

5.  Mice lacking p27(Kip1) display increased body size, multiple organ hyperplasia, retinal dysplasia, and pituitary tumors.

Authors:  K Nakayama; N Ishida; M Shirane; A Inomata; T Inoue; N Shishido; I Horii; D Y Loh; K Nakayama
Journal:  Cell       Date:  1996-05-31       Impact factor: 41.582

6.  Cyclin-dependent kinase inhibitor p57KIP2 in soft tissue sarcomas and Wilms'tumors.

Authors:  I Orlow; A Iavarone; S J Crider-Miller; F Bonilla; E Latres; M H Lee; W L Gerald; J Massagué; B E Weissman; C Cordón-Cardó
Journal:  Cancer Res       Date:  1996-03-15       Impact factor: 12.701

7.  Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest.

Authors:  D E Quelle; F Zindy; R A Ashmun; C J Sherr
Journal:  Cell       Date:  1995-12-15       Impact factor: 41.582

8.  Lack of p53 mutations and loss of heterozygosity in non-cultured human melanocytic lesions.

Authors:  T Papp; M Jafari; D Schiffmann
Journal:  J Cancer Res Clin Oncol       Date:  1996       Impact factor: 4.553

9.  A mutant p21 cyclin-dependent kinase inhibitor isolated from a Burkitt's lymphoma.

Authors:  K Bhatia; S Fan; G Spangler; M Weintraub; P M O'Connor; J G Judde; I Magrath
Journal:  Cancer Res       Date:  1995-04-01       Impact factor: 12.701

10.  Induction of different morphologic features of malignant melanoma and pigmented lesions after transformation of murine melanocytes with bFGF-cDNA and H-ras, myc, neu, and E1a oncogenes.

Authors:  S Ramon y Cajal; S Suster; R Halaban; E Filvaroff; G P Dotto
Journal:  Am J Pathol       Date:  1991-02       Impact factor: 4.307

View more
  118 in total

1.  p19ARF targets certain E2F species for degradation.

Authors:  F Martelli; T Hamilton; D P Silver; N E Sharpless; N Bardeesy; M Rokas; R A DePinho; D M Livingston; S R Grossman
Journal:  Proc Natl Acad Sci U S A       Date:  2001-03-27       Impact factor: 11.205

2.  New approaches to the biology of melanoma: a workshop of the National Institutes of Health Pathology B Study Section.

Authors:  Meenhard Herlyn; Martin Padarathsingh; Lynda Chin; Mary Hendrix; Dorothea Becker; Mark Nelson; Yves DeClerck; James McCarthy; Suresh Mohla
Journal:  Am J Pathol       Date:  2002-11       Impact factor: 4.307

Review 3.  Melanoma: from mutations to medicine.

Authors:  Hensin Tsao; Lynda Chin; Levi A Garraway; David E Fisher
Journal:  Genes Dev       Date:  2012-06-01       Impact factor: 11.361

Review 4.  Targeting the MAPK pathway in melanoma: why some approaches succeed and other fail.

Authors:  Gajanan S Inamdar; SubbaRao V Madhunapantula; Gavin P Robertson
Journal:  Biochem Pharmacol       Date:  2010-05-09       Impact factor: 5.858

5.  Conditional ablation of Ikkb inhibits melanoma tumor development in mice.

Authors:  Jinming Yang; Ryan Splittgerber; Fiona E Yull; Sara Kantrow; Gregory D Ayers; Michael Karin; Ann Richmond
Journal:  J Clin Invest       Date:  2010-06-07       Impact factor: 14.808

6.  Differentiation of human malignant melanoma cells that escape apoptosis after treatment with 9-nitrocamptothecin in vitro.

Authors:  P Pantazis; D Chatterjee; Z Han; J Wyche
Journal:  Neoplasia       Date:  1999-08       Impact factor: 5.715

Review 7.  Genetic alterations of PTEN in human melanoma.

Authors:  Almass-Houd Aguissa-Touré; Gang Li
Journal:  Cell Mol Life Sci       Date:  2011-11-11       Impact factor: 9.261

Review 8.  Delving into somatic variation in sporadic melanoma.

Authors:  Vijay Walia; Euphemia W Mu; Jimmy C Lin; Yardena Samuels
Journal:  Pigment Cell Melanoma Res       Date:  2012-02-13       Impact factor: 4.693

9.  Cooperative regulation of the cell division cycle by the protein kinases RAF and AKT.

Authors:  Amer M Mirza; Stephan Gysin; Nisar Malek; Kei-ichi Nakayama; James M Roberts; Martin McMahon
Journal:  Mol Cell Biol       Date:  2004-12       Impact factor: 4.272

10.  Activated Kras and Ink4a/Arf deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma.

Authors:  Andrew J Aguirre; Nabeel Bardeesy; Manisha Sinha; Lyle Lopez; David A Tuveson; James Horner; Mark S Redston; Ronald A DePinho
Journal:  Genes Dev       Date:  2003-12-17       Impact factor: 11.361

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.